CNS fibrinolysis: A review of the literature with a pediatric emphasis

Pediatric Neurology

Volumn 18, Issue 1, 1998, Pages 15-21

  Hansen, Anne R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; PLASMIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BRAIN HEMORRHAGE; BRAIN VASOSPASM; DRUG CONTRAINDICATION; DRUG INDICATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; HYDROCEPHALUS; MENINGITIS; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

EID: 0031953212     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(97)00127-6     Document Type: Review

References (63)

1. [1] Robbins KC, Barlow GH, Nguyen G, Samama MM. Comparison of plasminogen acivators. Semin Thromb Hemost 1987;13:131-8.
2. [2] Kleven MR. Comparison of thrombolytic agents: Mechanism of action, efficacy, and safety. Heart Lung 1988;17:750-5.
3. [3] The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932-36.
4. [4] Verstraete M, Bory M, Collen D, et al. Randomised trial of intravenous recombinant tissue type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985;1: 842-7.
5. [5] Marder VJ, Sherry S. Thrombolytic therapy: Current status. N Engl J Med 1988;318:1512-20.
6. [6] Urokinase Pulmonary Embolism Trial Study Group. Urokinase-streptokinase embolism trial. JAMA 1974;229:1606-13.
7. [7] Usui M, Saito N, Hoya K, Todo T. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: A retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone. Neurosurgery 1994;34:235-44.
8. [8] Porter JM, Acinapura AJ, Kapp JP, Silver D. Fibrinolysis in the central nervous system. Neurology 1969;19:47-52.
9. [9] Porter JM, Acinapura AJ, Kapp JP, Silver D. Fibrinolytic activity of the spinal fluid and meninges. Surg Forum 1966;17:425-7.
10. [10] Takashima S, Koga M, Tanaka K. Fibrinolytic activity of human brain and cerebrospinal fluid. Br J Exp Pathol 1969;50:533-9.
11. [11] Okada Y, Tsuchiya T, Tada T, Mishima T, Suzuki T. Experimental study on plasminogen activator and trypsin inhibitor system in the cerebrospinal fluid and brain in cases of trauma and shock. No To Shinkei 1966;18:784-7.
12. [12] Albrechtsen OK, Storm O, Claassen M. Fibrinolytic activity in some human body fluids. Scand J Clin Lab Invest 1958;10:310-18.
13. [13] Hinderson P, Heidrich R, Endler S. Haemostasis in cerebrospinal fluid. Basic concept of antifibrinolytic therapy of subarachnoid haemorrhage. Acta Neurochir Suppl 1984;34:1-77.
14. [14] Corrigan JJ, Sleeth JJ, Jeter M, Lox CD. Newborn's fibrinolytic mechanism: Components and plasmin generation. Am J Hematol 1989;32:273-8.
15. [15] Gibson B. Neonatal haemostasis. Arch Dis Child 1989:64: 503-6.
16. [16] Stewart GT. Fibrinolytic therapy in meningitis and ventriculitis. J Clin Pathol 1964;17:355-9.
17. [17] Newman RL, Stewart GT. The use of fibrinolytic activators in meningitis and similar conditions. Arch Dis Child 1965;40:235-42.
18. [18] Hellinger J, Vogel G. Studies on the fibrinolytic activity of cerebrospinal fluid and the effect of PAMBA (In German). Folia Haematol 1967;87:61-7.
19. [19] Whitelaw A. Endogenous fibrinolysis in neonatal cerebrospinal fluid. Eur J Pediatr 1993;928-30.
20. [20] Whitelaw A, Creighton L, Gaffney P. Fibrinolysis in cerebrospinal fluid after intraventricular haemorrhage. Arch Dis Child 1991;66: 808-9.
21. [21] Whitelaw A, Mowinckel MC, Larsen ML, Rokas E, Abildgaard U. Intraventricular streptokinase increases cerebrospinal fluid D dimer in preterm infants with posthaemorrhagic ventricular dilation. Acta Paediatr 1994;83:270-2.
22. [22] Whitelaw A, Mowinckel MC, Fellman V, Abildgaard U. Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Eur J Pediatr 1996;155:117-9.
23. [23] Kennady JC. Investigations of the early fate and removal of subarachnoid blood. Pac Med Surg 1967;75:163-8.
24. [24] Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with urokinase in a canine model. Part 1: Canine intraventricular blood cast model. Neurosurgery 1986;19:540-6.
25. [25] Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with urokinase in a canine model. Part 2: In vitro safety study of intraventricular urokinase. Neurosurgery 1986;19:547-52.
26. [26] Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with urokinase in a canine model. Part 3: Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus. Neurosurgery 1986;19:553-72.
27. [27] Narayan RK, Narayan TM, Katz DA, Kornblith PL, Murano G. Lysis of intracranial hematomas with urokinase in a rabbit model. J Neurosurg 1985;62:580-6.
28. [28] Mayfrank L, Kissler J, Raoofi R, et al. Ventricular dilatation in experimental intraventricular hemorrhage in pigs. Characterization of cerebrospinal fluid dynamics and the effects of fibrinolytic treatment. Stroke 1997;28:141-8.
29. [29] Peterson EW, Choo SH, Lewis AJ, Lach B, Bormanis J. Lysis of blood clot and experimental treatment of subarachnoid hemorrhage. In: Wilkins RH, ed. Cerebral Arterial Spasm. Baltimore: Williams and Wilkins, 1985:625-7.
30. [30] Findlay JM, Weir BKA, Steinke D, Tanabe T, Gordon P, Grace M. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. J Neurosurg 1988;69: 723-35.
31. [31] Findlay JM, Weir BKA, Gordon P, Grace M, Baughman R. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm. Neurosurgery 1989;24:491-8.
32. [32] Findlay JM, Weir BKA, Kanamura K, et al. Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: Dosage study in a primate model and review of the literature. Can J Neurol Sci 1989;16:28-40.
33. [33] Findlay JM, Weir BKA, Kanamura K, Grace M, Baughman R. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage. Neurosurgery 1990;26:201-6.
34. [34] Seifert V, Eisert WG, Stolke D, Goetz C. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 1989;25:590-8.
35. [35] Brinker T, Seifert V, Stolke D, Effect of intrathecal fibrinolysis on cerebrospinal fluid reabsorption after experimental subarachnoid hemorrhage. Neurosurgery 1991;74:789-93.
36. [36] Brinker T, Seifert V, Dietz H. Subacute hydrocephalus after experimental subarachnoid hemorrhage: Its prevention by intrathecal Fibrinolysis with recombinant tissue plasminogen activator. Neurosurgery 1992;31:306-12.
37. [37] Harriton GB, Findlay JM, Weir BKA, Kasuya H, Grace MGA, Mielke BW. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarchnoid clot and chronic vasospasm in a primate model. Neurosurgery 1993;33:691-7.
38. [38] Kajimoto Y, Ohta T, Kuroiwa T. Comparison of intrathecally administered tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs. Neurosurgery 1997;40:572-7.
39. [39] Todo T, Masaaki U, Takakura K. Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase. J Neurosurg 1991;74:81-6.
40. [40] Shen PH, Matsuoka Y, Kawajiri K, et al. Treatment of intraventricular hemorrhage using urokinase. Neurol Med Chir 1990;30: 329-33.
41. [41] Findlay JM, Weir BKA, Stollery DA. Lysis of intraventricular hematoma with tissue plasminogen activator. J Neurosurg 1991;74: 803-7.
42. [42] Findlay JM, Grace MGA, Weir BKA. Treatment of intraventricular hemorrhage with tissue plasminogen activator. Neurosurgery 1993;32:941-7.
43. [43] Mayfrank L, Lippitz B, Groth M, Bertalanffy H, Gilsbach JM. Effect of recombinant tissue plasminogen activator on clot lysis and ventricular dilatation in the treatment of severe intraventricular haemorrhage. Acta Neurochir 1993;122:32-8.
44. [44] Kodoma N, Sasaki T, Kawakami M, et al. Prevention of vasospasm: Cisternal irrigation therapy with urokinase and ascorbic acid. In: Sano K, Takakura K, Kassell NF, Sasaki T, eds. Cerebral Vasospasm: Proceedings of the IVth International Conference on Cerebral Vasospasm. Tokyo: University of Tokyo Press, 1990:292-6.
45. [45] Findlay JM, Weir BKA, Kassell NF, Disney LB, Grace MGA. Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage. J Neurosurg 1991;75:181-8.
46. [46] Mizoi K, Yoshimoto T, Takahashi A. Fujiwara S, Koshu K, Sugawara T. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. J Neurosurg 1993;78:430-7.
47. [47] Ohman J, Servo A, Heiskanen O. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1991;75:197-201.
48. [48] Stolke D, Seifert V. Single intracisternal bolus of recombinant tissue plasminogen activator in patients with aneurysmal subarachnoid hemorrhage: Preliminary assessment of efficacy and safety in an open clinical trial. Neurosurgery 1992;30:877-81.
49. [49] Tanabe T, Arimitsu M, Morimoto M, Kurisaka M, Mori K. The effect of intracranial thrombolytic therapy with tissue-type plasminogen activator on subarachnoid clot and chronic vasospasm. In: Sano K, Takakura K, Kassell NF, Sasaki T, eds. Cerebral vasospasm. Tokyo: University of Tokyo Press, 1990:321-3.
50. [50] Zabramski JM, Spetzler RF, Lee KS, et al. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1991;75:189-96.
51. [51] Findlay JM, Kassell NF, Weir BKA, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995;37:168-76.
52. [52] Weir B, Findlay JM. Comment. Neurosurgery 1992;30:881.
53. [53] Doi E, Moriwaki H, Komai N, Iwamoto M. Stereotactic evacuation of intracerebral hematomas. Neurol Med Chir 1982;22:461-7.
54. [54] Matsumoto K, Hondo H. CT guided stereotaxic evacuation of hypertensive intracerebral hematomas. J Neurosurg 1984;61:440-8.
55. [55] Cathie IAB. Bacterial fibrinolysin, its possible therapeutic application in tuberculous meningitis. J Clin Pathol 1949;2:73-6.
56. [56] Cathie IAB, MacFarlane JCW. Adjuvants to streptomycin in treating tuberculous meningitis in children. Lancet 1950;ii:784-8.
57. [57] Eadie MG. Personal communication from Eadie to Fletcher, 1952 (Ref. 8). In: Fletcher A. The preparation of partially purified plasmin, and an account of its intrathecal use in patients. J Clin Invest 1954;33:1242-51.
58. [58] Lorber J. Streptokinase as an adjunct in the treatment of tuberculous meningitis. Lancet 1951;1:1334-7.
59. [59] Fletcher AP. The preparation of partially purified plasmin, and an account of its intrathecal use in patients. J Clin Invest 1954;33: 1242-51.
60. [60] Ringelova J. Streptokinase in the therapy of purulent meningitis of newborns and sucklings. Cesk Pediatr 1976;31:163-6.
61. [61] Whitelaw A, Rivers RPA, Creightori L, Gaffney P. Low dose intraventricular fibrinolytic treatment to prevent posthaemorrhagic hydrocephalus. Arch Dis Child 1992;67:12-4.
62. [62] Whitelaw A, Saliba E, Fellman V, Mowinckel M-C, Acolet D, Marlow N. Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. Arch Dis Child 1996;75:F20-6.
63. [63] Hudgins RJ, Boydston WR, Hudgins PA, Adler SR. Treatment of intraventricular hemorrhage in the premature infant with urokinase. Pediatr Neurosurg 1994;20:190-7.